Drug class
Immune Checkpoint Inhibitors clinical trials
A class of medicines: the studies that test any of its 258 members, each study once. Members are as MeSH files each medicine’s actions, and as the NCI Thesaurus classes newer ones.
Medicines in this class
Studies that test each. A study of two counts under both, and once above.
And 218 more, each tested in fewer studies.
Studies by the year they started
8,297 studies that test it; most in 2021 (829); 22 more planned to start later
| Year | Studies |
|---|---|
| 1995 | 2 |
| 1997 | 1 |
| 2000 | 2 |
| 2001 | 2 |
| 2002 | 8 |
| 2003 | 10 |
| 2004 | 5 |
| 2005 | 10 |
| 2006 | 19 |
| 2007 | 20 |
| 2008 | 19 |
| 2009 | 19 |
| 2010 | 18 |
| 2011 | 35 |
| 2012 | 53 |
| 2013 | 72 |
| 2014 | 118 |
| 2015 | 238 |
| 2016 | 388 |
| 2017 | 620 |
| 2018 | 686 |
| 2019 | 735 |
| 2020 | 809 |
| 2021 | 829 |
| 2022 | 764 |
| 2023 | 769 |
| 2024 | 694 |
| 2025 | 714 |
| 2026 | 638 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2,707 · Other 5,613
Bristol-Myers Squibb (287) · M.D. Anderson Cancer Center (230) · National Cancer Institute (NCI) (225) · Sun Yat-sen University (220) · Merck Sharp & Dohme LLC (203) · Fudan University (182) · Hoffmann-La Roche (137) · AstraZeneca (126)
Studies
Open first, then newest update. How each study uses a medicine is read from its arms, and is right about nine times in ten.
Testing one of them · 8,320
- Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With DurvalumabEnrolling by invitationPhase 3AstraZenecaNCT05303532Written as Durvalumab
- Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA TrialNot yet recruitingPhase 2University of WashingtonNCT07332351Written as Durvalumab
- Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)Not yet recruitingPhase 1National Institute of Neurological Disorders and Stroke (NINDS)NCT07388550Written as Keytruda
- Neoadjuvant Belzutifan Plus Pembrolizumab in High-Risk, Locally Advanced Clear Cell Renal Cell CarcinomaNot yet recruitingPhase 2Peter MacCallum Cancer Centre, AustraliaNCT07840001Written as Pembrolizumab
- A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) ABBV-706 in Combination With Alveltamig and Atezolizumab for Adults Participants With Extensive Stage-Small Cell Lung CancerNot yet recruitingPhase 2AbbVieNCT07895043Written as Atezolizumab
- A Study of Perioperative Adebrelimab Plus Chemotherapy Versus Adjuvant Therapy in Patients With Resectable NSCLCNot yet recruitingPhase 3West China HospitalNCT07895238Written as Adebrelimab
- A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung CancerNot yet recruitingPhase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07896005Written as Adebrelimab Injection
- A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) ABBV-706 in Combination With Tarlatamab and Atezolizumab in Adult Participants With Extensive Stage-Small Cell Lung CancerNot yet recruitingPhase 2AbbVieNCT07895056Written as Atezolizumab
- Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsRecruitingPhase 2National Cancer Institute (NCI)NCT03866382Written as Ipilimumab
- Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCCRecruitingPhase 2Fujian Medical University Union HospitalNCT06510660Written as adebrelimab
- Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid TumorsRecruitingPhase 2BeiGeneNCT03736889Written as Tislelizumab (BGB-A317)
- Chemotherapy With or Without Immunotherapy for Peritoneal MesotheliomaRecruitingPhase 2National Cancer Institute (NCI)NCT05001880Written as Atezolizumab
- Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular CarcinomaRecruitingPhase 2University of California, IrvineNCT04472767Written as Nivolumab
- Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract CancerRecruitingPhase 2/3National Cancer Institute (NCI)NCT04628767Written as Durvalumab
- Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])RecruitingPhase 3National Cancer Institute (NCI)NCT04267848Written as Pembrolizumab
- BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot StudyRecruitingPhase 2National Cancer Institute (NCI)NCT05136196Written as Nivolumab
- A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)RecruitingPhase 3Regeneron PharmaceuticalsNCT06246916Written as fianlimab
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabRecruitingPhase 3National Cancer Institute (NCI)NCT05675410Written as Nivolumab
- Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN StudyRecruitingPhase 2/3National Cancer Institute (NCI)NCT05987241Written as Relatlimab
- Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated SarcomasRecruitingPhase 3National Cancer Institute (NCI)NCT06422806Written as Pembrolizumab
See all 8,320 studies that test one of the immune checkpoint inhibitors →
Codes
What other systems call Immune Checkpoint Inhibitors · ClinicalTrials.gg INT006847
- MeSH (NLM) D000082082Immune Checkpoint InhibitorsOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000082082 | Immune Checkpoint Inhibitors | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.